
Auron Therapeutics is a clinical-stage biotechnology company focused on developing life-saving therapies by targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory diseases. Utilizing their proprietary AI/ML-powered platform, AURIGIN™, they map cancer cell states to identify drivers of disease and develop targeted therapies. Their lead product, AUTX-703, is in Phase 1 clinical trials for advanced hematologic malignancies, addressing cancers with high mortality rates such as acute myeloid leukemia, small-cell lung cancer, and neuroendocrine prostate cancer. The company combines expertise in biology, medicinal chemistry, and computational science, working closely with leading physician-scientists to deliver effective and durable treatments. Auron Therapeutics aims to transform cancer treatment by focusing on cell state drug development to offer patients longer, higher quality lives.

Auron Therapeutics is a clinical-stage biotechnology company focused on developing life-saving therapies by targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory diseases. Utilizing their proprietary AI/ML-powered platform, AURIGIN™, they map cancer cell states to identify drivers of disease and develop targeted therapies. Their lead product, AUTX-703, is in Phase 1 clinical trials for advanced hematologic malignancies, addressing cancers with high mortality rates such as acute myeloid leukemia, small-cell lung cancer, and neuroendocrine prostate cancer. The company combines expertise in biology, medicinal chemistry, and computational science, working closely with leading physician-scientists to deliver effective and durable treatments. Auron Therapeutics aims to transform cancer treatment by focusing on cell state drug development to offer patients longer, higher quality lives.
Stage: Clinical-stage — AUTX-703 in first-in-human Phase 1
Lead program: AUTX-703 — first-in-class, oral KAT2A/B degrader
Platform: AURIGIN™ — AI/ML multi-omics platform for cell-state target discovery and biomarkers
Funding (select rounds): Series A $48M (Jul 20, 2022); Series B $27M (Feb 4, 2025) — at least $75M disclosed
Key regulatory update: AUTX-703 granted FDA Fast Track designation for relapsed/refractory AML; IND cleared to initiate clinical development
Oncology — modulation of cancer cell-state plasticity; applications also include inflammatory disease.
2018
Biotechnology
$12.75M
$48M
$27M
Announced alongside FDA IND clearance to initiate clinical development of AUTX-703.
“DCVC Bio led Series A and Series B; other disclosed investors and participants include Apollo Health Ventures, Arkin Bio Ventures, Casdin Capital, Polaris Partners, Qiming Venture Partners USA, Eli Lilly, BrightEdge, Franklin Berger, and Mubadala Capital.”